Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 22.57 as of 2026-10-06T21:39:02.897Z.
Consensus retrieved: 2026-10-06T17:52:06.739Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:39:02.897Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5ba1a7ae2545dd241011b344210ba2dd7fcd9a347687a5f40438e3bec48b98ab
Forward PE Ratio (22.57) = Dated Quote Price ($9.33) / Consensus Forward EPS ($0.41)
FORWARD PE RATIO
22.57
SECTOR MEDIAN · HEALTHCARE
19.75
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+14.28%
vs the sector median at left
Viemed Healthcare, Inc.
Market Cap
$355.36M
Forward PE Ratio
22.57
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Viemed Healthcare, Inc. (VMD) | $355.36M | 22.57 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | N/A |
| Embecta Corp. (EMBC)vs › | $353.00M | 3.38 |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 36.53 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | N/A |
Trailing P/E
25.6
reported TTM EPS
Forward P/E
22.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.41 implies +13.9% EPS growth vs the reported trailing $0.36.
At the dated quote price of $9.33, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.41 | $0.39 – $0.42 | 2 | 22.6x |
| 2027-12-31 | $0.54 | $0.49 – $0.59 | 2 | 17.2x |
| 2028-12-31 | $0.69 | $0.50 – $0.88 | 2 | 13.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
